Literature DB >> 18607207

Update in the epidemiology of Parkinson's disease.

Alexis Elbaz1, Frédéric Moisan.   

Abstract

PURPOSE OF REVIEW: In the past 18 months, several important studies on the epidemiology of Parkinson's disease have been published. In particular, large cohorts have identified sufficient incident patients with Parkinson's disease to study risk or protective factors of Parkinson's disease; one of the important recent events in the field is the publication of some of their findings. RECENT
FINDINGS: We will first review findings of descriptive studies on the frequency of the disease and its geographic or temporal distribution. We will then summarize the findings of analytical studies dealing with risk or protective factors in the fields of dietary and lifestyle factors (cigarette smoking, coffee and tea drinking, uric acid, dairy products), environmental exposures (pesticides, lead, manganese, welding), hormonal factors (oophorectomy), vascular risk factors (diabetes, hypertension, cholesterol level), pharmacoepidemiology (NSAIDs, statins), and familial aggregation.
SUMMARY: Epidemiologic studies have consistently found that some exposures are inversely (e.g., cigarette smoking) or positively associated with Parkinson's disease (e.g., pesticides), while their findings are, at the present time, less consistent for other exposures (e.g., NSAIDs, vascular risk factors). Finally, recent studies have investigated new research fields (e.g., hormonal factors, uric acid, pharmacoepidemiology) and additional data need to be collected.

Entities:  

Mesh:

Year:  2008        PMID: 18607207     DOI: 10.1097/WCO.0b013e3283050461

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  48 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 2.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

Review 5.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

6.  Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

Authors:  Xiomara A Pérez; Maryka Quik
Journal:  Mol Cell Pharmacol       Date:  2011

7.  Optimizing disease progression study designs for drug effect discrimination.

Authors:  Sebastian Ueckert; Stefanie Hennig; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-27       Impact factor: 2.745

8.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

9.  The effects of aging vs. α7 nAChR subunit deficiency on the mouse brain transcriptome: aging beats the deficiency.

Authors:  Merav Kedmi; Avi Orr-Urtreger
Journal:  Age (Dordr)       Date:  2010-06-05

Review 10.  Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.

Authors:  Alain Lekoubou; Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  BMC Public Health       Date:  2014-06-26       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.